KalVista Pharmaceuticals, Inc.
KALV
$13.05
-$0.26-1.95%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.97% | -67.11% | -52.86% | -59.75% | -69.74% |
| Total Depreciation and Amortization | 19.18% | 10.63% | 15.23% | 16.06% | 16.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.51% | 338.43% | -42.80% | -11.63% | 441.76% |
| Change in Net Operating Assets | -30.53% | 641.96% | -94.41% | 45.25% | 1,364.73% |
| Cash from Operations | -167.22% | -18.53% | -99.96% | -50.47% | 33.27% |
| Capital Expenditure | -1,773.33% | -26.32% | -5,300.00% | -250.00% | 78.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.59% | 227.80% | 70.81% | 89.53% | -1,954.57% |
| Cash from Investing | 97.36% | 227.08% | 70.45% | 89.48% | -1,931.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.09% | 19,809.51% | 130.47% | 1,370.59% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -94.71% | -- | -- | -- | 17,607.67% |
| Cash from Financing | -96.90% | 53,341.20% | 130.47% | 1,370.59% | 454,942.42% |
| Foreign Exchange rate Adjustments | 4,645.95% | -101.13% | 167.61% | 39.29% | -208.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -508.44% | 465.10% | 17.88% | 100.86% | 130.31% |